Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
